Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Talk with your healthcare provider often
According to the FDA's press release it agreed to approve the drug for obesity based on three randomised, double-blind, placebo-controlled trials during which more than 2,600 patients received Wegovy for up to 68 weeks and more than 1,500 patients received placebo (US FDA 2021)
The ultimate cost to the federal government of the Medicare GLP-1 Bridge will depend on actual participation numbers and adherence during the 18-month program, as well as potential cost offsets from savings that might accrue over time due to beneficiary health improvements from GLP-1 use for weight reduction and weight management
Dart RC, Mullins ME, Matoushek T, et al
Obesity: tirzepatide can achieve a more than 20% body weight reduction Participants in the trial were adults with obesity (BMI 30 kg/m) and overweight (BMI 27 kg/m) with comorbidities
US$ 23.44
US$ 20.67
US$ 28.73
US$ 29.66
